Skip to main content

Advertisement

SpringerLink
Log in

The Pharmacologic Management of Voiding Dysfunction, Stress Incontinence and the Overactive Bladder in Men and Women Who Have Had Prior Treatment for Pelvic Malignancies With Surgery or Radiation Therapy

  • Cancer-Associated Voiding Dysfunction (A Peterson, Section Editor)
  • Published:
Current Bladder Dysfunction Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This review seeks to enlighten the reader on the pharmacologic management of stress urinary incontinence and overactive bladder after surgery or radiation therapy for pelvic malignancy.

Recent Findings

There is little study in the last decade on pharmacologic management of stress urinary incontinence, while more studies on overactive bladder have been published in the urologic literature over the last 5 years. Few studies in the gynecologic and colorectal literature on either topic have been completed.

Summary

There is little data on which to base the pharmacologic management of stress urinary incontinence and overactive bladder in the cancer survivor population. More studies are needed to validate the efficacy of the standard drug treatments for these conditions in the general population as compared to the unique population of cancer survivors, who may have altered vascular, neurologic, and structural anatomy that reduces the efficacy of these drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017; doi:10.3322/caac.21387.

    Google Scholar 

  2. Wein AJ, Barrett DM. Voiding function and dysfunction : a logical and practical approach. Chicago: Year Book Medical Publishers; 1988.

    Google Scholar 

  3. DeLancey J, Gosling J, Creed K, Dixon J, Delmas V, Landon D, et al. Gross anatomy and cell biology of the lower urinary tract. In: Abrams P, Cardozo L, Khoury S, Wein A, editors. Incontinence, second international consultation on incontinence. Plymouth: Health Publication; 2002. p. 17–82.

    Google Scholar 

  4. Zderic S, Levin R, Wein A. Voiding function and dysfunction: a relevant anatomy, physiology, and pharmacology, and molecular biology. Adult and pediatric urology. 1996;3:1159–219.

    Google Scholar 

  5. Fowler Jr FJ, Barry MJ, Lu-Yao G, Wasson J, Roman A, Wennberg J. Effect of radical prostatectomy for prostate cancer on patient quality of life: results from a Medicare survey. Urology. 1995;45(6):1007–13. discussion 13-5

    Article  PubMed  Google Scholar 

  6. • Wei JT, Dunn RL, Marcovich R, Montie JE, Sanda MG. Prospective assessment of patient reported urinary continence after radical prostatectomy. J Urol. 2000;164(3 Pt 1):744–8. This reference higlights an important study in urology on patient-reported outcomes after radical prostatectomy. As noted in the reference below (#7), while definitions of continence, it is likely most important to understand how the continence (or lack thereof) is viewed from that patient’s perspective, not the surgeon’s.

    Article  CAS  PubMed  Google Scholar 

  7. Krupski TL, Saigal CS, Litwin MS. Variation in continence and potency by definition. J Urol. 2003;170(4 Pt 1):1291–4. doi:10.1097/01.ju.0000085341.63407.46.

    Article  PubMed  Google Scholar 

  8. Bregendahl S, Emmertsen KJ, Lindegaard JC, Laurberg S. Urinary and sexual dysfunction in women after resection with and without preoperative radiotherapy for rectal cancer: a population-based cross-sectional study. Color Dis. 2015;17(1):26–37. doi:10.1111/codi.12758.

    Article  CAS  Google Scholar 

  9. Jayne DG, Guillou PJ, Thorpe H, Quirke P, Copeland J, Smith AM, et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(21):3061–8. doi:10.1200/JCO.2006.09.7758.

    Article  Google Scholar 

  10. Marijnen CA, van de Velde CJ, Putter H, van den Brink M, Maas CP, Martijn H, et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(9):1847–58. doi:10.1200/JCO.2005.05.256.

    Article  Google Scholar 

  11. Zwaans BM, Chancellor MB, Lamb LE. Modeling and treatment of radiation cystitis. Urology. 2016;88:14–21. doi:10.1016/j.urology.2015.11.001.

    Article  PubMed  Google Scholar 

  12. Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, et al. Fourth international consultation on incontinence recommendations of the international scientific committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29(1):213–40. doi:10.1002/nau.20870.

    Article  CAS  PubMed  Google Scholar 

  13. Shah EF, Huddy SP. A prospective study of genito-urinary dysfunction after surgery for colorectal cancer. Color Dis. 2001;3(2):122–5.

    Article  CAS  Google Scholar 

  14. Tekkis PP, Cornish JA, Remzi FH, Tilney HS, Strong SA, Church JM, et al. Measuring sexual and urinary outcomes in women after rectal cancer excision. Dis Colon rectum. 2009;52(1):46–54. doi:10.1007/DCR.0b013e318197551e.

  15. Nesbakken A, Nygaard K, Bull-Njaa T, Carlsen E, Eri LM. Bladder and sexual dysfunction after mesorectal excision for rectal cancer. Br J Surg. 2000;87(2):206–10. doi:10.1046/j.1365-2168.2000.01357.x.

    Article  CAS  PubMed  Google Scholar 

  16. Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368(5):436–45. doi:10.1056/NEJMoa1209978.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Halpern JA, Sedrakyan A, Hsu WC, Mao J, Daskivich TJ, Nguyen PL, et al. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer. Cancer. 2016;122(16):2496–504. doi:10.1002/cncr.30101.

    Article  PubMed  Google Scholar 

  18. Zelefsky MJ, Poon BY, Eastham J, Vickers A, Pei X, Scardino PT. Longitudinal assessment of quality of life after surgery, conformal brachytherapy, and intensity-modulated radiation therapy for prostate cancer. Radiother Oncol. 2016;118(1):85–91. doi:10.1016/j.radonc.2015.11.035.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Rutledge TL, Heckman SR, Qualls C, Muller CY, Rogers RG. Pelvic floor disorders and sexual function in gynecologic cancer survivors: a cohort study. Am J Obstet Gynecol. 2010;203(5):514 e1–7. doi:10.1016/j.ajog.2010.08.004.

    Article  Google Scholar 

  20. Noronha AF, Mello de Figueiredo E, Rossi de Figueiredo Franco TM, Candido EB, Silva-Filho AL. Treatments for invasive carcinoma of the cervix: what are their impacts on the pelvic floor functions? International braz j urol : official journal of the Brazilian Society of Urology. 2013;39(1):46–54. doi:10.1590/S1677-5538.IBJU.2013.01.07.

    Article  Google Scholar 

  21. Manchana T. Long-term lower urinary tract dysfunction in gynecologic cancer survivors. Asian Pacific journal of cancer prevention : APJCP. 2011;12(1):285–8.

    PubMed  Google Scholar 

  22. Chen GD, Lin LY, Wang PH, Lee HS. Urinary tract dysfunction after radical hysterectomy for cervical cancer. Gynecol Oncol. 2002;85(2):292–7. doi:10.1006/gyno.2002.6614.

    Article  PubMed  Google Scholar 

  23. Benedetti-Panici P, Zullo MA, Plotti F, Manci N, Muzii L, Angioli R. Long-term bladder function in patients with locally advanced cervical carcinoma treated with neoadjuvant chemotherapy and type 3-4 radical hysterectomy. Cancer. 2004;100(10):2110–7. doi:10.1002/cncr.20235.

    Article  PubMed  Google Scholar 

  24. Ralph G, Tamussino K, Lichtenegger W. Urological complications after radical abdominal hysterectomy for cervical cancer. Baillieres Clin Obstet Gynaecol. 1988;2(4):943–52.

    Article  CAS  PubMed  Google Scholar 

  25. Herwig R, Bruns F, Strasser H, Pinggera GM, Micke O, Rehder P, et al. Late urologic effects after adjuvant irradiation in stage I endometrial carcinoma. Urology. 2004;63(2):354–8. doi:10.1016/j.urology.2003.09.040.

    Article  CAS  PubMed  Google Scholar 

  26. Matulonis UA, Kornblith A, Lee H, Bryan J, Gibson C, Wells C, et al. Long-term adjustment of early-stage ovarian cancer survivors. Int J Gynecol Cancer. 2008;18(6):1183–93. doi:10.1111/j.1525-1438.2007.01167.x.

    Article  CAS  PubMed  Google Scholar 

  27. Wein AJ. Pathophysiology and classification of lower urinary tract dysfunction: overview. Campbell-Walsh urology. 10th ed. Philadelphia: Elsevier Saunders; 2011. p. 1834–46.

    Google Scholar 

  28. Andersson K-E, Appell R, Awad S, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Khoury S, Wein A, editors. Incontinence. Plymouth: Health Publications Ltd; 2002. p. 481–511.

    Google Scholar 

  29. Tsakiris P, de la Rosette JJ, Michel MC, Oelke M. Pharmacologic treatment of male stress urinary incontinence: systematic review of the literature and levels of evidence. Eur Urol. 2008;53(1):53–9. doi:10.1016/j.eururo.2007.09.037.

    Article  CAS  PubMed  Google Scholar 

  30. Diokno AC, Taub M. Ephedrine in treatment of urinary incontinence. Urology. 1975;5(5):624–5.

    Article  CAS  PubMed  Google Scholar 

  31. Alhasso A, Glazener CM, Pickard R, N'Dow J. Adrenergic drugs for urinary incontinence in adults. Cochrane Database Syst Rev. 2005;3:CD001842. doi:10.1002/14651858.CD001842.pub2.

    Google Scholar 

  32. Smith AL, Wein AJ. Urinary incontinence: pharmacotherapy options. Ann Med. 2011;43(6):461–76. doi:10.3109/07853890.2011.564203.

    Article  CAS  PubMed  Google Scholar 

  33. Fuller MA, Borovicka MC, Jaskiw GE, Simon MR, Kwon K, Konicki PE. Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. J Clin Psychiatry. 1996;57(11):514–8.

    Article  CAS  PubMed  Google Scholar 

  34. Awad SA, Downie JW, Kiruluta HG. Alpha-adrenergic agents in urinary disorders of the proximal urethra. Part I. Sphincteric incontinence. Br J Urol. 1978;50(5):332–5.

    Article  CAS  PubMed  Google Scholar 

  35. Stewart BH, Banowsky LH, Montague DK. Stress incontinence: conservative therapy with sympathomimetic drugs. J Urol. 1976;115(5):558–9.

    CAS  PubMed  Google Scholar 

  36. Wells TJ, Brink CA, Diokno AC, Wolfe R, Gillis GL. Pelvic muscle exercise for stress urinary incontinence in elderly women. J Am Geriatr Soc. 1991;39(8):785–91.

    Article  CAS  PubMed  Google Scholar 

  37. Fleming GA. The FDA, regulation, and the risk of stroke. N Engl J Med. 2000;343(25):1886–7. doi:10.1056/NEJM200012213432510.

    Article  CAS  PubMed  Google Scholar 

  38. Weil EH, Eerdmans PH, Dijkman GA, Tamussino K, Feyereisl J, Vierhout ME, et al. Randomized double-blind placebo-controlled multicenter evaluation of efficacy and dose finding of midodrine hydrochloride in women with mild to moderate stress urinary incontinence: a phase II study. Int Urogynecol J Pelvic Floor Dysfunct. 1998;9(3):145–50.

    Article  CAS  PubMed  Google Scholar 

  39. Radley SC, Chapple CR, Bryan NP, Clarke DE, Craig DA. Effect of methoxamine on maximum urethral pressure in women with genuine stress incontinence: a placebo-controlled, double-blind crossover study. Neurourol Urodyn. 2001;20(1):43–52.

    Article  CAS  PubMed  Google Scholar 

  40. Gnad H, Burmucic R, Petritsch P, Steindorfer P. Conservative therapy of female stress incontinence. Double-blind study with the alpha-sympathomimetic midodrin. Fortschr Med. 1984;102(20):578–80.

    CAS  PubMed  Google Scholar 

  41. Morita T. Experimental studies for urinary incontinence. Effect of beta 2-agonists on the vesicourethral function. Nihon Hinyokika Gakkai zasshi The japanese journal of urology. 1989;80(11):1597–604.

    CAS  PubMed  Google Scholar 

  42. Ishiko O, Ushiroyama T, Saji F, Mitsuhashi Y, Tamura T, Yamamoto K, et al. Beta(2)-adrenergic agonists and pelvic floor exercises for female stress incontinence. Int J Gynaecol Obstet. 2000;71(1):39–44.

    Article  CAS  PubMed  Google Scholar 

  43. Noguchi M, Eguchi Y, Ichiki J, Yahara J, Noda S. Therapeutic efficacy of clenbuterol for urinary incontinence after radical prostatectomy. International journal of urology : official journal of the Japanese Urological Association. 1997;4(5):480–3.

    Article  CAS  Google Scholar 

  44. Zozikov B, Kunchev SI, Varlev C. Application of clenbuterol in the treatment of urinary incontinence. Int Urol Nephrol. 2001;33(3):413–6.

    Article  CAS  PubMed  Google Scholar 

  45. Yasuda K, Kawabe K, Takimoto Y, Kondo A, Takaki R, Imabayashi K, et al. A double-blind clinical trial of a β2-adrenergic agonist in stress incontinence. Int Urogynecol J. 1993;4(3):146–51.

    Article  Google Scholar 

  46. Malallah MA, Al-Shaiji TF. Pharmacological treatment of pure stress urinary incontinence: a narrative review. Int Urogynecol J. 2015;26(4):477–85. doi:10.1007/s00192-014-2512-9.

    Article  PubMed  Google Scholar 

  47. Creasman WT. Hormone replacement therapy after cancers. Curr Opin Oncol. 2005;17(5):493–9.

    CAS  PubMed  Google Scholar 

  48. Andersson K, Wein A. Pharmacologic management of lower urinary tract storage and emptying failure. Campbell-Walsh urology. 10th ed. Philadelphia: Saunders Elsevier; 2011.

    Google Scholar 

  49. Moehrer B, Hextall A, Jackson S. Oestrogens for urinary incontinence in women. Cochrane Database Syst Rev. 2003;2:CD001405. doi:10.1002/14651858.CD001405.

    Google Scholar 

  50. Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC, et al. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol. 2003;170(4 Pt 1):1259–63. doi:10.1097/01.ju.0000080708.87092.cc.

    Article  CAS  PubMed  Google Scholar 

  51. Zinner NR, Koke SC, Viktrup L. Pharmacotherapy for stress urinary incontinence: present and future options. Drugs. 2004;64(14):1503–16.

    Article  PubMed  Google Scholar 

  52. Lovvik A, Muller S, Patel HR. Pharmacological treatment of post-prostatectomy incontinence: what is the evidence? Drugs Aging. 2016;33(8):535–44. doi:10.1007/s40266-016-0388-8.

    Article  PubMed  Google Scholar 

  53. Cornu JN, Merlet B, Ciofu C, Mouly S, Peyrat L, Sebe P, et al. Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial. Eur Urol. 2011;59(1):148–54. doi:10.1016/j.eururo.2010.10.031.

    Article  CAS  PubMed  Google Scholar 

  54. Alan C, Eren AE, Ersay AR, Kocoglu H, Basturk G, Demirci E. Efficacy of duloxetine in the early management of urinary continence after radical prostatectomy. Curr Urol. 2015;8(1):43–8. doi:10.1159/000365688.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Filocamo MT, Li Marzi V, Del Popolo G, Cecconi F, Villari D, Marzocco M, et al. Pharmacologic treatment in postprostatectomy stress urinary incontinence. Eur Urol. 2007;51(6):1559–64. doi:10.1016/j.eururo.2006.08.005.

    Article  CAS  PubMed  Google Scholar 

  56. Fink KG, Huber J, Wurnschimmel E, Schmeller NT. The use of duloxetine in the treatment of male stress urinary incontinence. Wien Med Wochenschr. 2008;158(3–4):116–8. doi:10.1007/s10354-007-0494-7.

    Article  PubMed  Google Scholar 

  57. Collado Serra A, Rubio-Briones J, Puyol Payas M, Iborra Juan I, Ramon-Borja JC, Solsona Narbon E. Postprostatectomy established stress urinary incontinence treated with duloxetine. Urology. 2011;78(2):261–6. doi:10.1016/j.urology.2011.03.006.

    Article  PubMed  Google Scholar 

  58. Schlenker B, Gratzke C, Reich O, Schorsch I, Seitz M, Stief CG. Preliminary results on the off-label use of duloxetine for the treatment of stress incontinence after radical prostatectomy or cystectomy. Eur Urol. 2006;49(6):1075–8. doi:10.1016/j.eururo.2006.01.038.

    Article  CAS  PubMed  Google Scholar 

  59. Zahariou A, Papaioannou P, Kalogirou G. Is HCl duloxetine effective in the management of urinary stress incontinence after radical prostatectomy? Urol Int. 2006;77(1):9–12. doi:10.1159/000092927.

    Article  CAS  PubMed  Google Scholar 

  60. Mandel P, Preisser F, Graefen M, Steuber T, Salomon G, Haese A, et al. High chance of late recovery of urinary and erectile function beyond 12 months after radical prostatectomy. Eur Urol. 2016; doi:10.1016/j.eururo.2016.09.030.

    Google Scholar 

  61. Norton PA, Zinner NR, Yalcin I, Bump RC, Duloxetine Urinary Incontinence Study G. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol. 2002;187(1):40–8.

    Article  CAS  PubMed  Google Scholar 

  62. Rovner E, Wein A, Cardozo L, Staskin D. Drug treatment of voiding dysfunction. The textbook of female urology and urogynecology. 1st ed. London: Isis Medical Media; 2001. p. 357–407.

    Google Scholar 

  63. Reid GF, Fitzpatrick JM, Worth PH. The treatment of patients with urinary incontinence after prostatectomy. Br J Urol. 1980;52(6):532–4.

    Article  CAS  PubMed  Google Scholar 

  64. Gilja I, Radej M, Kovacic M, Parazajder J. Conservative treatment of female stress incontinence with imipramine. J Urol. 1984;132(5):909–11.

    CAS  PubMed  Google Scholar 

  65. Lin HH, Sheu BC, Lo MC, Huang SC. Comparison of treatment outcomes for imipramine for female genuine stress incontinence. Br J Obstet Gynaecol. 1999;106(10):1089–92.

    Article  CAS  PubMed  Google Scholar 

  66. Honda M, Kawamoto B, Morizane S, Hikita K, Muraoka K, Sejima T et al. Impact of postoperative phosphodiesterase type 5 inhibitor treatment on lower urinary tract symptoms after robot-assisted radical prostatectomy: a longitudinal study. Scand J Urol. 2016:1–5. doi:10.1080/21681805.2016.1250810.

  67. Canat L, Guner B, Gurbuz C, Atis G, Caskurlu T. Effects of three-times-per-week versus on-demand tadalafil treatment on erectile function and continence recovery following bilateral nerve sparing radical prostatectomy: results of a prospective, randomized, and single-center study. Kaohsiung J Med Sci. 2015;31(2):90–5. doi:10.1016/j.kjms.2014.11.005.

    Article  PubMed  Google Scholar 

  68. Patel HR, Ilo D, Shah N, Cuzin B, Chadwick D, Andrianne R, et al. Effects of tadalafil treatment after bilateral nerve-sparing radical prostatectomy: quality of life, psychosocial outcomes, and treatment satisfaction results from a randomized, placebo-controlled phase IV study. BMC Urol. 2015;15:31. doi:10.1186/s12894-015-0022-9.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Gacci M, Ierardi A, Rose AD, Tazzioli S, Scapaticci E, Filippi S, et al. Vardenafil can improve continence recovery after bilateral nerve sparing prostatectomy: results of a randomized, double blind, placebo-controlled pilot study. J Sex Med. 2010;7(1 Pt 1):234–43. doi:10.1111/j.1743-6109.2009.01471.x.

    Article  CAS  PubMed  Google Scholar 

  70. Hyndman ME, Bivalacqua TJ, Mettee LZ, Su LM, Trock BJ, Pavlovich CP. Nightly sildenafil use after radical prostatectomy has adverse effects on urinary convalescence: results from a randomized trial of nightly vs on-demand dosing regimens. Canadian Urological Association journal = Journal de l'Association des urologues du Canada. 2015;9(11–12):414–9. doi:10.5489/cuaj.3169.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology. 2002;60(5 Suppl 1):7–12. discussion

    Article  PubMed  Google Scholar 

  72. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–14. discussion 14-5. doi:10.1016/j.eururo.2006.09.019.

  73. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760–6.

    Article  CAS  PubMed  Google Scholar 

  74. Thiruchelvam N, Cruz F, Kirby M, Tubaro A, Chapple CR, Sievert KD. A review of detrusor overactivity and the overactive bladder after radical prostate cancer treatment. BJU Int. 2015;116(6):853–61. doi:10.1111/bju.13078.

    Article  PubMed  Google Scholar 

  75. Plotti F, Angioli R, Zullo MA, Sansone M, Altavilla T, Antonelli E, et al. Update on urodynamic bladder dysfunctions after radical hysterectomy for cervical cancer. Crit Rev Oncol Hematol. 2011;80(2):323–9. doi:10.1016/j.critrevonc.2010.12.004.

    Article  PubMed  Google Scholar 

  76. Hazewinkel MH, Sprangers MA, van der Velden J, van der Vaart CH, Stalpers LJ, Burger MP, et al. Long-term cervical cancer survivors suffer from pelvic floor symptoms: a cross-sectional matched cohort study. Gynecol Oncol. 2010;117(2):281–6. doi:10.1016/j.ygyno.2010.01.034.

    Article  CAS  PubMed  Google Scholar 

  77. Morrison J, Steers W, Brading A, Blok B, Fry C, De Groat W, et al. Neurophysiology and neuropharmacology. Inc. 2002;2:85–161.

    Google Scholar 

  78. Leone Roberti Maggiore U, Salvatore S, Alessandri F, Remorgida V, Origoni M, Candiani M, et al. Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. Expert Opin Drug Metab Toxicol. 2012;8(11):1387–408. doi:10.1517/17425255.2012.714365.

    Article  PubMed  Google Scholar 

  79. Oger S, Behr-Roussel D, Gorny D, Lebret T, Validire P, Cathelineau X, et al. Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle. Br J Pharmacol. 2010;160(5):1135–43. doi:10.1111/j.1476-5381. 2010.00748.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Behr-Roussel D, Oger S, Caisey S, Sandner P, Bernabe J, Alexandre L, et al. Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats. Eur Urol. 2011;59(2):272–9. doi:10.1016/j.eururo.2010.10.037.

    Article  CAS  PubMed  Google Scholar 

  81. Groutz A, Blaivas JG, Chaikin DC, Weiss JP, Verhaaren M. The pathophysiology of post-radical prostatectomy incontinence: a clinical and video urodynamic study. J Urol. 2000;163(6):1767–70.

    Article  CAS  PubMed  Google Scholar 

  82. Steiner MS. Continence-preserving anatomic radical retropubic prostatectomy: the “no-touch” technique. Curr Urol Rep. 2000;1(1):20–7.

    Article  CAS  PubMed  Google Scholar 

  83. Porena M, Mearini E, Mearini L, Vianello A, Giannantoni A. Voiding dysfunction after radical retropubic prostatectomy: more than external urethral sphincter deficiency. Eur Urol. 2007;52(1):38–45. doi:10.1016/j.eururo.2007.03.051.

    Article  PubMed  Google Scholar 

  84. Kim HS, Kim K, Ryoo SB, Seo JH, Kim SY, Park JW, et al. Conventional versus nerve-sparing radical surgery for cervical cancer: a meta-analysis. J Gynecol Oncol. 2015;26(2):100–10. doi:10.3802/jgo.2015.26.2.100.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3(1):46–53.

    Article  CAS  PubMed  Google Scholar 

  86. • Andersson K, Chapple C, Cardozo L, Cruz F, Hashim H, Michel M, et al. Incontinence. In: Abrams P, Cardozo L, Khoury S, Wein AJ, editors. 5th International Consultation on Incontinence. Paris: ICUD-EAU; 2013. p. 623–728. This citation should be considered a “bread and butter” reference for anyone treating voiding dysfunction, both in cancer survivors and the general population. It provides a good overview of incontinence including etiology, workup, and treatments.

    Google Scholar 

  87. Bittner N, Merrick GS, Brammer S, Niehaus A, Wallner KE, Butler WM, et al. Role of trospium chloride in brachytherapy-related detrusor overactivity. Urology. 2008;71(3):460–4. doi:10.1016/j.urology.2007.10.023.

    Article  PubMed  Google Scholar 

  88. Liss MA, Morales B, Skarecky D, Ahlering TE. Phase 1 clinical trial of Vesicare (solifenacin) in the treatment of urinary incontinence after radical prostatectomy. Journal of endourology / Endourological Society. 2014;28(10):1241–5. doi:10.1089/end.2014.0342.

    Article  Google Scholar 

  89. Bianco FJ, Albala DM, Belkoff LH, Miles BJ, Peabody JO, He W, et al. A randomized, double-blind, solifenacin succinate versus placebo control, phase 4, multicenter study evaluating urinary continence after robotic assisted radical prostatectomy. J Urol. 2015;193(4):1305–10. doi:10.1016/j.juro.2014.09.106.

    Article  CAS  PubMed  Google Scholar 

  90. Shim M, Kim J, Park S, Choi SK, Lee SM, Huh KO, et al. The therapeutic effect of solifenacin succinate on the recovery from voiding dysfunction after radical prostatectomy in men with clinically localized prostate cancer: a prospective, randomized, controlled study. Urology. 2015;85(5):1123–9. doi:10.1016/j.urology.2015.01.022.

    Article  PubMed  Google Scholar 

  91. Winters JC, Appell RA, Rackley RR. Urodynamic findings in postprostatectomy incontinence. Neurourol Urodyn. 1998;17(5):493–8.

    Article  CAS  PubMed  Google Scholar 

  92. Sacco E, Bientinesi R. Mirabegron: a review of recent data and its prospects in the management of overactive bladder. Ther Adv Urol. 2012;4(6):315–24. doi:10.1177/1756287212457114.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Khullar V, Amarenco G, Angulo JC, Cambronero J, Hoye K, Milsom I, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63(2):283–95. doi:10.1016/j.eururo.2012.10.016.

    Article  CAS  PubMed  Google Scholar 

  94. Nitti VW, Chapple CR, Walters C, Blauwet MB, Herschorn S, Milsom I, et al. Safety and tolerability of the beta3-adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised phase III trials and of a 1-year randomised phase III trial. Int J Clin Pract. 2014;68(8):972–85. doi:10.1111/ijcp.12433.

    Article  CAS  PubMed  Google Scholar 

  95. Chen H, Wang F, Yu Z, Zhang Y, Liu C, Dai S, et al. Efficacy of daily low-dose tadalafil for treating overactive bladder: results of a randomized, double-blind, placebo-controlled trial. Urology. 2016; doi:10.1016/j.urology.2016.11.008.

    Google Scholar 

  96. Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol. 2006;49(4):644–50. doi:10.1016/j.eururo.2005.12.010.

    Article  CAS  PubMed  Google Scholar 

  97. Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2017;197(2S):S216–S23. doi:10.1016/j.juro.2016.10.109.

    Article  CAS  PubMed  Google Scholar 

  98. Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416–22. doi:10.1016/j.juro.2010.08.021.

    Article  CAS  PubMed  Google Scholar 

  99. Cheng T, Shuang WB, Jia DD, Zhang M, Tong XN, Yang WD, et al. Efficacy and safety of onabotulinumtoxinA in patients with neurogenic detrusor overactivity: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2016;11(7):e0159307. doi:10.1371/journal.pone.0159307.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Habashy D, Losco G, Tse V, Collins R, Chan L. Botulinum toxin (onabotulinumtoxinA) in the male non-neurogenic overactive bladder: clinical and quality of life outcomes. BJU Int. 2015;116(Suppl 3):61–5. doi:10.1111/bju.13110.

    Article  CAS  PubMed  Google Scholar 

  101. Mittal S, Machado DG, Jabbari B. OnabotulinumtoxinA for treatment of focal cancer pain after surgery and/or radiation. Pain Med. 2012;13(8):1029–33. doi:10.1111/j.1526-4637.2012.01437.x.

    Article  PubMed  Google Scholar 

  102. • Amundsen CL, Richter HE, Menefee SA, Komesu YM, Arya LA, Gregory WT, et al. OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial. JAMA. 2016;316(13):1366–74. doi:10.1001/jama.2016.14617. This reference highlights an important study on the comparison of two different treatment options for refractory OAB: Botox and neuromodulation. This randomized trial highlights the relative success rates of the two therapies and compares outcomes and side effects. This article should be read by any provider who offers sacral neuromodulation and/or onabotulinumtoxinA injections

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Alabama-Birmingham, FOT 1120, 1720 2nd Ave South, Birmingham, AL, 35294, USA

    J. Patrick Selph & Ava Saidian

Authors
  1. J. Patrick Selph
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ava Saidian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Patrick Selph.

Ethics declarations

Conflict of Interest

Drs. Selph and Saidian declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Cancer-Associated Voiding Dysfunction

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Patrick Selph, J., Saidian, A. The Pharmacologic Management of Voiding Dysfunction, Stress Incontinence and the Overactive Bladder in Men and Women Who Have Had Prior Treatment for Pelvic Malignancies With Surgery or Radiation Therapy. Curr Bladder Dysfunct Rep 12, 143–152 (2017). https://doi.org/10.1007/s11884-017-0417-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11884-017-0417-4

Keywords

Search

Navigation